Publications by authors named "N O'Donovan"
Background: Expanded access programs (EAPs) allow cancer patients with unmet clinical need to obtain access to pre-authorisation treatments. There is no standardised process for implementing these programs nationally, and real-world data on their impact is lacking.
Aims: This study aimed to evaluate the prevalence of such EAPs and their impact in a cancer centre.
Purpose: Drug efflux transporter associated multi-drug resistance (MDR) is a potential limitation in the use of taxane chemotherapies for the treatment of metastatic melanoma. ABT-751 is an orally bioavailable microtubule-binding agent capable of overcoming MDR and proposed as an alternative to taxane-based therapies.
Methods: This study compares ABT-751 to taxanes in vitro, utilizing seven melanoma cell line models, publicly available gene expression and drug sensitivity databases, a lung cancer cell line model of MDR drug efflux transporter overexpression (DLKP-A), and drug efflux transporter ATPase assays.
Article Synopsis
- The phase II trial ICORG10-05 examined the effects of chemotherapy in combination with trastuzumab, lapatinib, or both on patients with HER2+ breast cancer, focusing on changes in circulating immune cells.
- Researchers analyzed blood samples to assess immune cell cytotoxicity, phenotype, and genotype before and after neo-adjuvant treatment, along with evaluating the impact of pembrolizumab on immune activity.
- Results showed that treatment reduced the cytotoxic capability of immune cells, altered their composition, and identified potential biomarkers for treatment response through the analysis of pembrolizumab's effects on immune cell activity.
Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR) are associated with poor outcomes in TNBC. Targeting IGF1R has failed clinically.
View Article and Find Full Text PDF